Skip to main content
Truhout big pharma

Before COVID-19, Big Pharma Was Neglecting Vaccine and Antiviral Research

Drug companies have historically pleased investors by promoting vaccine development programs during disease outbreaks, then quietly dropping them later, according to Dana Brown, director of The Next System Project, a research and development lab for political-economic alternatives. Despite an outbreak raging in the Republic of Congo, the British drug maker GlaxoSmithKline recently gave up its effort to develop a vaccine for Ebola and handed off its research to a nonprofit lab. Ebola is deadly but relatively rare globally, and the market was too small to generate significant profits. In 2017, the massive French drug maker Sanofi pulled out of a partnership with the U.S. Army to develop a vaccine for the mosquito-borne Zika virus.

Read the entire article at Truthout.

Publication date: 2020-04-23
Parent publication: Truthout
Publication URL: https://truthout.org/articles/before-covid-19-big-pharma-was-neglecting-vaccine-and-antiviral-research/

More related work

Medicine Cost

Americans deserve publicly owned generic drugs

Bold policies could have saved America’s largest generic drug plant, but it’s never too late to start putting communities first.

read more
Illustration courtesy of United Nations

All health is public health: Busting the myths of choice and commodity

For decades, we have been sold a myth of private health. It is a myth that our health is largely a product of individual choices and personal responsibilities. It is a myth that our healthcare is a service that private corporations can provide, and for which we must pay to survive. But the COVID-19

read more
Neil McInroy (Source: Coop News)

Neil McInroy joins TDC to advise stepped-up community wealth building program

The former CEO of a leading UK economic think tank will be central in helping build capacity to offer powerful new technical assistance to cities and local authorities pursuing community wealth building strategies.

read more